DB视讯

Dr. Jun Zhu (朱俊), aged 47, has served as the chief executive officer of the Company since July 2023 and an executive Director of the Company since August 2023.

Dr. Zhu joined the Group in January 2021 and has been the senior vice president and chief medical officer of Henlius Biopharmaceutical, and the senior vice president and chief medical officer, chief financial officer and the president of the Company. Dr. Zhu holds directorship and managerial positions in certain other subsidiaries of the Company.

Prior to joining the Company, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager (Greater China) of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司). Dr. Zhu obtained a bachelor’s degree in clinical medicine from Fudan University (復旦大學) in the PRC in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2018, and a doctoral
degree in health management from University of Montpellier in France in June 2024. 

Mr. Qiyu Chen (陳啟宇), aged 53, has been a non-executive Director of the Company since February 2010 and served as the Chairman of the Board of the Company from December 2018 to November 2021. 

Mr. Chen joined Fosun Pharma Group in April 1994, successively serving as secretary to the board, general manager, vice chairman, executive director, chairman and other positions of Fosun Pharma from April 1994 to October 2020, and has served as a non-executive director of Fosun Pharma since October 2020. Mr. Chen currently serves as the chairman of the board of Fosun High Tech, the executive director and the co-chief executive officer of Fosun International, the non-executive director and vice chairman of the board
of Sinopharm. Mr. Chen previously served as the non-executive director of Gland Pharma, the director of Beijing Sanyuan Foods Co., Ltd.* (北京三元食品股份有限公司) (Shanghai Stock Exchange stock code: 600429). In addition, Mr. Chen holds directorships in various companies invested by Fosun International and its affiliated companies.

Mr. Chen has been a member of the 14th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, the chairman of Shanghai Chamber of Biopharmaceutical Commerce, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, and the honorary chairman of China Medical Pharmaceutical Material Association, etc. Mr. Chen was awarded “Asia’s Best CEO” by Corporate Governance Asia, etc. Mr. Chen received a bachelor’s degree in genetics from Fudan University in the PRC in July 1993 and an EMBA degree from China Europe International Business School in the PRC in September 2005.

Mr. Yuqing Chen (陳玉卿), aged 50, has served as non-executive Director of the Company since August 2025.

Mr. Chen joined Fosun Pharma Group in January 2010. Mr. Chen is currently an executive director and the chairman of the board of directors of Fosun Pharma, a senior vice president of Fosun International, and a non-executive director of Sinopharm. Mr. Chen has been a deputy supervisor of the human resources department, a deputy general manager of the human resources department, the general manager of the human resources department, an assistant to the president, the general manager of the human resources department, a vice president, a senior vice president, the co-president and chief executive officer of Fosun Pharma; the chairman of the board of directors of Shanghai Fosun Health Technology (Group) Co., Ltd.*(上海復星健康科技(集團)有限公司), a subsidiary of Fosun Pharma, from August 2020 to May 2021 and from October 2022 to present; and a non-executive Director of Fosun Pharma from September 2024 to April 2025, and has served as an executive Director and the chairman of the Board of Fosun Pharma from April 2025. In addition, Mr. Chen holds directorship and managerial positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Mr. Chen served as a teacher at the School of Materials of Shanghai University; and successively served as a human resources manager of Yanfeng Visteon Automotive Trim Systems Co., Ltd.* (延鋒偉世通汽車飾件系統有限公司) (currently renamed as Yanfeng Automotive Trim Systems Co., Ltd.* (延鋒汽車飾件系統有限公司)), Yanfeng Visteon (Beijing) Automotive Trim Systems Co., Ltd.* (延鋒偉世通(北京)汽車飾件系統有限公司) and Shanghai Yanfeng Johnson Controls Seating Co., Ltd.* (上海延鋒江森座椅有限公司); a development manager of the human resources department of Shanghai Alison (Group) Co., Ltd.* (上海埃力生(集團)有限公司); the Central China human resources manager of Schindler (China) Elevator Co. Ltd.* (迅達(中國)電梯有限公司); the senior human resources integration manager of Global Mart Limited* (購寶商業集團); and the chief human resources director of Kubao Information Technology (Shanghai) Co., Ltd.* (酷寶信息技術(上海)有限公司). Mr. Chen obtained a bachelor’s degree in engineering from Shanghai University in July 1997.

Ms. Xiaohui Guan (關曉暉), aged 55, has been a non-executive Director of the Company since December 2018.

Ms. Guan joined Fosun Pharma Group in May 2000. Ms. Guan is currently an executive director and a co-chairman of Fosun Pharma, the vice president of Fosun International and the chairman of the board of supervisors of Sinopharm. Ms. Guan has been an assistant to the president, general manager of the finance department, the chief accountant, a vice president and the chief accountant, the senior vice president and chief financial officer, the executive president and chief financial officer of Fosun Pharma. Ms. Guan served as the executive director of Fosun Pharma since December 2021, the vice chairman of Fosun Pharma from January 2022 to April 2025, and a co-chairman of Fosun Pharma since April 2025. In addition, Ms. Guan holds directorship positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Ms. Guan worked at the Jiangxi Branch of the Industrial and Commercial Bank of China. Ms. Guan obtained a bachelor’s degree in economics from Jiangxi University of Finance and Economics (江西財經大學) in the PRC in June 2000 and acquired a master’s degree in professional accountancy from the Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as a Chinese Certified Public Accountant (CPA), a member of the Association of Chartered Certified Accountants (ACCA) and a Senior Accountant.

Dr. Yi Liu (劉毅), aged 50, has been a non-executive Director of the Company since August 2025.

Dr. Liu joined Fosun Pharma Group in November 2015. Dr. Liu currently serves as an executive director, chief executive officer and president of Fosun Pharma and an executive director and chairman of the board of directors of Sisram Medical. Dr. Liu has been the chief technology officer of the Medical Devices Division, the vice president and the senior vice president of Fosun Pharma, and has been serving as chief executive officer and president of Fosun Pharma since June 2025. In addition, Dr. Liu holds directorship and managerial positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Dr. Liu was a trainee in Young Cadre Training Class of China National Academy of Governance (國家行政學院青年幹部培訓班); served a deputy section chief of Medical Devices Division and a section chief of Market Supervision Department of State Food and Drug Administration (now known as National Medical Products Administration); and successively served as the deputy head and head of Beijing Institute of Medical Device Testing (北京市醫療器械檢驗所). Dr. Liu obtained a bachelor degree in engineering from Beijing Institute of Technology in July 1998, a master degree in management from Peking University in January 2006, and a doctorate degree in biomedical engineering from Beijing University of Aeronautics and Astronautics in June 2021.

Dr. Xingli Wang, aged 63, has been a non-executive Director of the Company since August 2023.

Dr. Wang joined Fosun Pharma Group in January 2023 and served as an executive president of Fosun Pharma from January 2023 to June 2025, and has been the co-president of Fosun Pharma from June 2025. In addition, Dr. Wang holds directorship in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Dr. Wang engaged in postdoctoral research in cardiovascular science at The University of New South Wales, Australia (“UNSW”). He was successively engaged in clinical residency rotation at Prince of Wales Hospital in Sydney, and served as a senior lecturer in cardiovascular medicine at UNSW and a director of cardiothoracic surgery research and tenured professor at Baylor College of Medicine, USA. He served as a medical director of Schering-Plough Corporation (New York Stock Exchange stock code: SGP, merged into Merck & Co., Inc. in 2009). He worked in Novartis AG (New York Stock Exchange stock code: NVS), mainly serving as project director, global project clinical head, head of Novartis Global Drug R&D (China) and general manager of Biomedical Research Institute (China).

Dr. Wang obtained a bachelor’s degree in medicine from Shandong Medical College (merged into Shandong University in 2000) in July 1985 and a doctorate degree in cardiovascular science from UNSW in October 1991. Dr. Wang also holds a license to practice medicine in Australia.

Mr. Tak Young So (蘇德揚), aged 55, has been an independent non-executive Director of the Company since September 2019.

Mr. So has been the founding and managing partner of FastLane Group since July 2012. He served as an independent non-executive director of Goodbaby International Holdings Limited (Stock Exchange stock code: 01086) from May 2022 to May 2025 and independent non-executive director of CARsgen Therapeutics Holdings Limited (Stock Exchange stock code: 02171) from June 2021 to June 2023.

Mr. So has more than 30 years of experience in finance, accounting, investment, and private equity businesses with global financial institutions and asset management companies. Mr. So served as an auditor at Ernst & Young, Hong Kong, as group audit and project manager of the strategic and performance improvement group in the Sydney office of Commonwealth Bank of Australia, as vice president of global capital market/Asia treasury and vice president of financial controls at Bank of America, Hong Kong, as head of finance and operations of consumer banking in Hong Kong, head of asset and liability management of Greater China/Asia Pacific, and chief financial officer of consumer, commercial and private banking in Hong Kong at ABN AMRO Bank N.V., Hong Kong, as chief financial officer at Hamon Investment Group, an affiliate of Bank of New York Mellon, as chief financial officer of the Asia Pacific of asset management division at Deutsche Bank, Hong Kong, as chief financial officer at PAG Capital, and as a partner at Prospere Capital Limited. Mr. So obtained a bachelor’s degree in accounting and finance and a master’s degree in business administration in banking from the University of Technology Sydney, Australia, in April 1994 and September 1998, respectively. Mr. So has been a fellow member of the Certified Practising Accountants Australia (CPA Australia) since August 2011.

Dr. Ruilin Song (宋瑞霖), aged 63, has been an independent non-executive Director of the Company since September 2019.

Dr. Song has been a non-executive director of Luye Pharma Group Ltd.* (綠葉製藥集團有限公司) (Stock Exchange stock code: 02186) since March 2017, an independent non-executive director of Simcere Pharmaceutical Group Limited* (先聲藥業集團有限公司) (Stock Exchange stock code: 02096) since November 2019, an independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd.* (加科思藥業集團有限公司) (Stock Exchange stock code: 01167) since December 2020, and an independent non-executive director of Mediwelcome Healthcare Management & Technology Inc.* (麥迪衛康健康醫療管理科技股份有限公司) (Stock Exchange stock code: 02159) since December 2020. Dr. Song served as an independent director of Shenzhen Chipscreen Biosciences Co., Ltd.* (深圳微芯生物有限公司) (SSE STAR Market stock code: 688321) from May 2018 to April 2024.

During the time he worked in the Legislative Affairs Office of the State Council, Dr. Song was mainly engaged in the legislative review of Chinese medicine and health laws for 22 years. He participated in all China’s medicine and health legislation activities from 1987 to 2006, in charge of the drafting and review of laws such as Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases and Law of the PRC on Medical Practitioners, and administrative regulations such as Regulations
on Medical Institutions, Administration of Medical Devices and Emergency Regulations on Public Health Emergencies, etc. Since 2007, Dr. Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA (中國醫藥創新促進會) have finalised dozens of research projects. Dr. Song has been the executive president of PhIRDA (formerly known as China Pharmaceutical Industry Research and Development Association (中國醫藥工業科研開發促進會)) from November 2009 to September 2019, the president of PhIRDA from September 2019 to September 2020, executive president of PhIRDA from September 2020 to June 2025, and senior president of PhIRDA since June 2025. Dr. Song also served as specially-invited expert of Talent Pool Participating in and Discussing State Affairs of the CPPCC, consultant expert of Participating in and Discussing State Affairs of the Chinese Peasants and Workers Democratic Party, executive deputy director of National Drug Policy and Industrial Development Research Center of China Pharmaceutical University, visiting researcher of Shanghai Jiao Tong University, member of Advisory Committee for Traditional Chinese Medicine Strategic Decision of National Medical Products Administration, vice chairman of China Alliance of Rare Diseases (CARD), director of Chinese Pharmacist Association and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions.

Dr. Song obtained a bachelor’s degree in laws from China University of Political Science and Law (中國政法大學) in June 1985, a master’s degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in November 2004 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University (中國藥科大學) in December 2018.

Mr. Yihao Zhang, aged 53, has been an independent non-executive Director of the Company since August 2025.

Mr. Zhang served as the global executive vice president of GE Healthcare, president and CEO of GE Healthcare China from July 2019 to July 2025, fully responsible for the strategy formulation, implementation, and operation of GE Healthcare in the Chinese market. Mr. Zhang successively held various positions at Danaher Corporation and its subsidiaries from March 2003 to June 2019, including China deputy general manager, general manager, vice president and general manager of Greater China, president of the Dental Products Business Platform for Greater China and Asia Pacific region, and senior vice president. Mr. Zhang served as the brand manager at P&G from May 2002 to August 2002; the financial analysis manager at TRW in the United States from July 1996 to May 2001.

Mr. Zhang previously served as the vice chairman of the Advanced Medical Technology Association in China, and was awarded the Shanghai “Magnolia Silver Award” in September 2021. Mr. Zhang received a bachelor’s degree in mathematics and economics from Ohio Wesleyan University in the United States in 1996, and a master’s degree in business administration from Kellogg School of Management at Northwestern University in the United States and a master’s degree in engineering management from the McCormick School of Engineering at Northwestern University in the United States in 2003, respectively.